SIS
NBIX icon

Sound Income Strategies’s Neurocrine Biosciences NBIX Stock Holding History

Sound Income Strategies’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-60
Closed -$5.83K – 981
2021
Q1 		$5.83K Hold
60
– – ﹤0.01% 596
2020
Q4 		$6K Hold
60
– – ﹤0.01% 554
2020
Q3 		$6K Buy
60
+10
+20% +$1.16K ﹤0.01% 521
2020
Q2 		$6K Hold
50
– – ﹤0.01% 480
2020
Q1 		$4K Hold
50
– – ﹤0.01% 494
2019
Q4 		$5K Buy
+50
New +$5.24K ﹤0.01% 463

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.84B AUM 22.63% 1-Year Est. Return

Sound Income Strategies's NBIX Position: Q2 2021 in Review

Sound Income Strategies sold out of Neurocrine Biosciences (NBIX) in Q2 2021, closing a stake of 60 shares — an estimated $5.83K sold.

Sound Income Strategies first reported a position in NBIX in Q4 2019 and held it in 6 quarters. The position peaked at $6K in Q4 2020. 409 funds tracked by Wall St. Rank hold NBIX as of Q2 2021.

  • Sound Income Strategies reported no remaining Neurocrine Biosciences position as of Q2 2021 after selling out during the quarter.
  • Sound Income Strategies sold 60 Neurocrine Biosciences shares in Q2 2021, an estimated $5.83K.
  • Sound Income Strategies first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 6 quarters.
  • Sound Income Strategies's Neurocrine Biosciences position peaked at $6K in Q4 2020.
  • 409 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2021.

Based on Sound Income Strategies's 13F filing for Q2 2021, filed 13 Jul 2021.